Skip Navigation

  1. Acerca de Nosotros
    1. Visión General
    2. Historia
    3. Oficinas
  2. Nuestra Experiencia
    1. Áreas de Trabajo
      1. Patentes
      2. Marcas
      3. Derecho de Autor
      4. Derecho Corporativo y Mercantil
      5. Litigio de Propiedad Intelectual y Resolución Alternativa de Disputas
      6. Práctica Regulatoria
      7. Otorgamiento de Licencias, Transferencia de Tecnología y Franquicias
      8. Anti-Piratería, Anti-Falsificación & Aplicación
    2. Grupos de la Industria
      1. Grupo de Abogados en Medios, Deportes y Entretenimiento
      2. Grupo de Abogados e Ingenieros en Ciencias de la Vida
  3. Nuestra Gente
    1. Socios
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. César Ramos, Jr.
      5. Antonio Belaunzarán
      6. Gustavo A. Alcocer
      7. José Ignacio de Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sánchez
    2. Asociados (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Asociados (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. Abogados / Ingenieros
    5. Administración de la firma
  4. Conocimiento & Recursos
    1. Artículos y Estudios de Casos
      1. Artículos sobre Marcas
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Artículos sobre Patentes
        1. Mexican Linkage Gazette April 2011
        2. Mexico issues regulations to approve biologic drugs
        3. Latin America Roundtable
        4. New regulations pending
        5. The International Comparative Guide
        6. Marketing authorization for pharmaceutical
        7. Approval of follow-on biologics in Mexico
        8. Patent Prosecution Highway in Mexico
        9. Life Sciences Handbook 2011 - Country Q&A
        10. Data Package Exclusivity (DPE)
        11. 35 more items...
      3. Artículos sobre Derecho de Autor
        1. Publicidad en redes sociales
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 97 more items...
      4. Artículos sobre Derecho Corporativo
        1. Mexico issues Personal Data Protection Rules
        2. A practical cross-border
        3. New registry for security interests
        4. The International Comparative Legal Guide to: Merger Control 2011
        5. The International Comparative Legal Guide to: Merger Control 2010
        6. Due diligence issues to consider in M&A
        7. Income expectations in licensing
        8. The reasons for valuation
        9. Amendments proposed to franchise regulation
      5. Artículos sobre Litigio y RAD
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Artículos sobre Derecho Regulatorio
        1. Recientes enmiendas a la Ley Federal de Protección al Consumidor
        2. Enmiendas en la Ley Federal de Protección al Consumidor
        3. Mexico issues Personal Data Protection Rules
        4. New Regulations Pending
        5. Marketing authorization for pharmaceutical products to foreign applicants
        6. Data Package Exclusivity (DPE)
        7. Supreme Court upholds the worth of formulation patents
        8. Pharmaceutical trademarks
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Advertising 2009
        11. 4 more items...
      7. Artículos sobre Licencias y Transferencia de Tecnología
        1. Creating a secure franchise system
      8. Artículos sobre Anti-piratería y Anti-falsificación
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 4 more items...
      9. Artículos en relación con Medios, Deportes y Entretenimiento
        1. Publicidad en redes sociales
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Artículos en relación con Ciencias de la Vida
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
  5. Oficinas
  6. Eventos
  7. Contacto

Español » Conocimiento & Recursos » Artículos y Estudios de Casos » Artículos sobre Derecho Regulatorio » New Regulations for pharma industry

New Regulations for pharma industry

por Juan Luis Serrano
Managing Intellectual Property, International Briefings, February 2008
On January 2, 2008 a Decree was published in the Official Gazette in Mexico modifying several provisions of the Regulations for Health Consumables of the Health Law, concerning important issues for the pharmaceutical industry.
The first relevant amendment is that these regulations eliminate the distinction between “generics” and “interchangeable generics”. Before the regulations were enacted, a generic registration could be obtained without proving interchangeability or bioequivalence. With these reforms, all genetic medicines will need to prove interchangeability with a medicine of reference.
Within the amendments concerning generic medicines, the specific requirement to prove safety and efficacy, which was previously contemplated in the regulations, is eliminated and is substituted by the need to prove interchangeability. This may have an impact on data package exclusivity issues, as reliance on the information contained in a reference product’s dossier seem to be necessary for the issuance of generic authorizations.
Additionally, the timelines for the MOH to decide upon the issuance of marketing authorizations are extended from 40 to 180 days for medicines that had been previously registered in Mexico, from 60 to 240 days for medicines registered abroad, from 90 to 180 for new molecules and from 90 to 180 for biological medicines.
Another change addressed in these reforms is the setting of rules concerning the extension of term of marketing authorizations. Accordingly, unless extended, marketing authorization will be in force for five years. The main requirements for these extensions are a technical report for interchangeability in the event of changes affecting the pharmacokinetics of the medicament and a pharmacovigilance report.
We are performing a through analysis on the impact of these reforms in both the R&D and the generics industry in our country, including judicial and other means to surmount any negative impacts of the reform.